Agilon Health Earnings Call: Profits Up, Growth Cautious

Agilon Health Inc ((AGL)) has held its Q1 earnings call. Read on for the main highlights of the call.

Agilon Health’s latest earnings call struck a cautiously optimistic tone. Management highlighted a sizable beat on first-quarter profitability and improving medical margins, underpinned by better risk adjustment data and disciplined cost control. Yet they also acknowledged headwinds from declining Medicare Advantage membership, lower year-over-year revenue and regulatory and Part D uncertainties.

Q1 Beat on Revenue Sparks Upward 2026 Revision

Agilon reported about $1.42 billion in Q1 revenue, topping the upper end of guidance thanks to stronger-than-expected risk adjustment income and a new full-risk contract. On the back of this upside, management lifted its full-year 2026 revenue outlook, with the midpoint now around $5.7 billion, signaling confidence in the underlying earnings power despite a shrinking member base.

Profitability Jumps as Medical Margin and EBITDA Improve

Adjusted EBITDA surged to $54 million in Q1 from $21 million a year earlier, while medical margin rose to $149 million from $128 million, underscoring better profitability and operating discipline. Management credited tighter OpEx control and particularly strong performance in ACO REACH, which helped offset pressure from lower membership and Part D reserving.

Risk Adjustment Data Pipeline Delivers Revenue Upside

A revamped data pipeline now provides clinical and claims information, plus risk scores, for roughly 85% of members, sharpening visibility into revenue drivers. With this enhanced view, Agilon lifted its expected risk-score improvement for the year to about 1.5% from 0.4%, a change that materially boosted Q1 revenue and underpins a roughly $50 million annual risk-adjustment benefit.

ACO REACH Shines with Benchmark Tailwinds

The ACO REACH segment generated roughly $27 million of adjusted EBITDA in Q1, beating internal expectations by about $5 million and emerging as a key profit contributor. Results were aided by a CMS adjustment that stripped out suspect urinary catheter and skin substitute costs from 2025 benchmarks, improving economics and validating the company’s value-based care approach.

Scaling Clinical Programs Shows Early Cost and Quality Wins

Agilon’s clinical initiatives, particularly its congestive heart failure pathway, are expanding across the network and showing measurable impact. The CHF program now covers around 90% of markets, cutting inpatient-first diagnoses from roughly 25% to below 5%, while adherence to guideline-based therapy and integrated pharmacy management are improving, pointing to future cost avoidance and quality gains.

Medical Cost Trend Eases with Better Claims Development

The company now expects its 2025 medical cost trend to be about 6.2%, down from a prior 6.5%, reflecting favorable claims development and more effective cost management. This lower trend supports the margins seen in Q1 and suggests Agilon is gaining traction in managing high-cost conditions, even as it prepares for uncertainty in future reimbursement models.

Financial Planning Stays Conservative Across Key Levers

Despite Q1 outperformance, Agilon is anchoring its full-year net cost trend outlook around 7%, a deliberately conservative stance recognizing limited early-year claims visibility. Management is also focused on tightening payer contracts, reducing exposure to Part D to below 15% and preserving liquidity, targeting at least $125 million in year-end cash plus off-balance-sheet ACO funds.

Medicare Advantage Membership Slide Weighs on Scale

Medicare Advantage membership fell to 426,000 in Q1 2026 from 491,000 a year earlier, a decline of about 13.2% that directly pressures top-line scale. Management linked the drop to earlier market exits, selective payer negotiations and a deliberate shift away from aggressive expansion, emphasizing that near-term membership contraction is the price of maintaining disciplined growth.

Revenue Down Year on Year Despite Rate Tailwinds

While Q1 revenue beat guidance, it declined about 7.2% year over year from roughly $1.53 billion to $1.42 billion, driven primarily by lower Medicare Advantage membership. Favorable risk adjustment and rate dynamics softened the blow, but the comparison underscores the tension between quality-focused, measured growth and the revenue pressures of operating with a smaller member base.

Part D Reserves Blur View of Underlying Performance

Agilon recorded additional reserves for Part D given limited reconciliation data early in the year, partially offsetting positive prior-year medical expense development. Because Part D costs are booked net against premium revenue, this creates timing noise and reserve risk, complicating investors’ ability to parse true underlying margin trends until later in the year.

Early-Year Cost Trend Set High on Limited Claims Data

With only partial visibility into paid claims for 2026, the company booked a Q1 cost trend of 7.4% while keeping its full-year net trend assumption at about 7%, effectively baking in caution. Management indicated that this conservative posture may obscure near-term variability, leaving room for upside if claims stabilize favorably as the year progresses.

Full-Year EBITDA Guide Lags Strong First Quarter

In a notable display of prudence, Agilon raised revenue and medical margin guidance but set full-year adjusted EBITDA at roughly $25 million, well below Q1’s $54 million. The company implied that early-year results benefited from favorable or potentially nonrecurring items and that it is assuming a more normalized, lower second-half profitability profile amid lingering regulatory and cost uncertainties.

Disciplined Growth Strategy Limits Near-Term Expansion

Management reiterated that the priority is deepening in-market execution rather than rapid new-market expansion, including a new full-risk contract modeled to breakeven in year one on roughly $200 million of revenue. While this approach may cap near-term revenue and membership growth, the company argues it lays the groundwork for more durable, less volatile earnings over time.

Regulatory Cloud from Emerging CMS Risk Model

Executives flagged the lack of clarity around CMS’s AI-inferred LEAD risk model, noting they cannot yet reliably quantify its impact on future risk scores and reimbursement. This uncertainty adds another layer of risk to long-term projections, even as current year results benefit from improved data capture and a more robust risk adjustment pipeline.

Guidance Balances Raised Expectations with Prudence

Agilon’s updated 2026 outlook calls for around $5.7 billion in revenue, roughly $375 million in medical margin and about $25 million in adjusted EBITDA, with Q2 guidance pointing to a step-down in margin from Q1 levels. Assumptions include a 1.5% risk-score lift, a $50 million risk-adjustment benefit, a 7% net cost trend and at least $125 million in year-end cash, underscoring a careful balance between growth and risk management.

Agilon’s earnings call painted a picture of a company executing well operationally while navigating structural and regulatory headwinds with deliberate caution. Investors heard a story of improving profitability, stronger data capabilities and disciplined cost control offset by shrinking membership, lower year-over-year revenue and conservative guidance that tempers near-term upside, but may reduce longer-term volatility.